#IR

As of February 27, 2026, National Indemnity Company, a wholly owned subsidiary of Berkshire Hathaway Inc., increased its voting rights ratio in our company’s shares from 9.54% to 10.07%, becoming the largest shareholder.

The exercise of the 23rd and 24th series stock acquisition rights was zero in February 2026, with no change in the number of unexercised stock acquisition rights, remaining at 1,050,000 units (105,000,000 shares) each.

In February 2026, margin transaction loans amounted to 550,539 hundred million yen, loans of securities were 294,123 hundred million yen, and net short stock balance was 123,251 hundred million yen.

The Company has decided to participate as an auxiliary defendant in the shareholder derivative lawsuit and will appropriately counter the plaintiff shareholders' claims as they are judged to be unfounded.

We announce that as of February 25, 2026, the voting rights holding ratio of Silchester International Investors LLP decreased from 10.25% to 9.23%, and the number of shares owned decreased from 12,596,100 shares to 11,346,100 shares.

Sold 5 listed securities between February 17 and 25, 2026, recording special profit of 1,818 million yen. To be reflected in fiscal year ending March 2026 financial statements.

On March 2, 2026, through a third-party allotment capital increase with Dai-ichi Life Holdings, Inc. as the allottee, 40,126,200 ordinary shares (8,076,664 newly issued shares and 32,049,536 treasury shares disposed) were issued at 435 yen per share, completing fund procurement of 17,454,897,000 yen.

ZOZO, Inc. entered into a 12.5 billion yen commitment line agreement on March 13, 2026, to prepare for future M&A funding needs.

At the shareholders’ meeting on May 29, 2026, approval is planned for the trade name change and partial amendment to articles of incorporation. The trade name will change from TKP Corporation to TKP Corporation (abbreviated), effective June 1, 2026.

Asuka Pharmaceutical Holdings Co., Ltd. has resolved to transition to a company with an audit and supervisory committee, subject to approval at the 5th Annual General Meeting of Shareholders scheduled for June 24, 2026.

No acquisition of own investment units in February 2026, total acquisition value 0 yen. Approved limit as of December 25, 2025 is 16,000 units and 1.5 billion yen.

JAL Group formulated a new growth strategy, "JAL Group Management Vision 2035," aiming for EBIT of over 350 billion yen by 2035, upwardly revised the EBIT forecast for the fiscal year ending March 2026 to 205 billion yen, and plans to increase dividends from 92 yen to 96 yen per share.